Member Info for RorkesDrift

All testing only works as a strategy if repeated continually. So once started then those enrolled it is 2-3 times per week.

10M people = 20-30M tests per week for at least six months and then its flu season so let's say 20M for 50weeks.

At £1 profit per test ......

Share price should at least double

Then consider Europe and then consider US..

These numbers are ex-Jina

Current MKT cap = £463M

Forget everything else how many tests would they need to sell to realise that

Contribution of say £1 per test

So 463m tests at 2M per day

231 days.

A) what about ex-Uk
B) will pandemic still be here in 6 months

So lots more even if its ex-jina

If they don't release an RNS can you see anyone selling at existing SP. In supply but demand = SP rise

https://www.bbc.co.uk/programmes/m000sm2g

Review of the papers.....

Jeez Hants you painted a picture there.

Missed but not forgotten

Oh hang on .....

Bump

Since you ask may I enquire whether you mean ex-jina

Perhaps the parade already taken place

President Bidding may already have visited the dressing rooms

They will want them to be American companies. There will be some of this with a more strategic view rather than a quick in and out

For the last 12 months I check my HL app more often than I care to mention. Press the button, do the finger print thing, select is a etc etc

I have been checking it a bit tonight but the SP hasn't changed. I then do some stuff on the calculator.

I'm not sure I can take the excitement.

Feet on the ground can wait til 7.59am Monday (59 mins after RNS).

SleepyDave - thinking league table update. Shall we say Wednesday?

https://open.spotify.com/track/1vLw8Ns5fqzXzkPQYhmR6i?si=kHEKuSuvR9GMqUOJXAZBtA&utm_source=copy-link

Croeso .....

Best post of the year. Centurion status.

...... Sets alarm 7 o'clock Monday

Entrance stage right

Given the uncertainty about the duration x volume (could be a lot but huge margins of error) then cost of entry would be huge. Therefore have to go via third party - quick, simple and limited capital requirement. Loss of margin agreed but actual return is likely to be higher.

Fairly easy to draw up a beauty parade of potentials - who has the most to lose.....

I have reliably been informed that during one of their regular horizon scanning exercises a large, well known American DX company performed a technical appraisal on Avactas technology. I cannot say anymore than this due to obvious reasons.

However, once again I believe my analysis to be exemplary and have pinned my colors (I have gone US speak now) to a timeline that may or not be right.

Exit stage left. (Echo's of praise be and what sounds like a large pork based food substance being prepared)

Couple things you need

1. Regulatory skill / FDA contacts
2. American brand
3. American manufacturing capacity

The most obvious way to secure all of these is a partnership. The least complicated way is licensing.

I fully expect an announcement next week rapidly followed by trading update.

I am getting the hang of this self assertive language but sometimes 1+1=3.

Anything else make sense ?

I like the approach but question the assumptions. 21M tests in a year would not be worth the govts effort. Just surveillance in schools or HCPs is far in excess of this.

Success rate for clinical trial at 10%. On one hand it is oncology - very very high attrition rate. That said the active ingredient is well known and efficacious.

Other drugs at peak sales of £1B - again not sure that is valid. The whole homing missile concept across multiple disease states.

£2.30 is good news but they need to pay more attention in class. The risk modeling approach is now on the curriculum of the Church of the Right Reverend and will replace cut and paste lessons

DoH - I know I'm more cynical but "Then what amounts to the greatest leap forward in cancer treatment in a generation".

Keep at it though - I need the money ;-)